GSK ends year on a high as HIV and specialty meds drive growth
British drugmaker GSK (LSE: GSK) reported higher revenue and earnings for both the fourth quarter and full year, reflecting strong demand for HIV and specialty medicines. Fourth-quarter revenue rose 6% to £8.6 billion (about $10.9 billion), while earnings per share increased 56%.
For the full year, revenue grew 4% to £32.7 billion, with earnings per share more than doubling, helped by improved operating leverage and lower legal and restructuring charges compared with the prior year. Wednesday’s update was the company’s first set of results since Luke Miels last month succeeded Emma Walmsley as chief executive.
Growth in the quarter was led by the HIV portfolio, including Dovato (dolutegravir/lamivudine) and long-acting injectable Cabenuva (cabotegravir/rilpivirine). Specialty medicines, spanning oncology, respiratory and immunology, also posted solid gains, while vaccines delivered modest growth.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze